A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of X4P-001 in Patients With WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of X4P-001 in Patients With WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs X4P 001 (Primary)
  • Indications WHIM syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms X4P-001-MKKA
  • Sponsors X4 Pharmaceuticals
  • Most Recent Events

    • 30 Jan 2017 According to a X4 Pharmaceuticals media release, first patient has been dosed in this trial.
    • 02 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top